SPRY vs. VKTX, AXSM, TGTX, KRYS, ADMA, SRRK, ALVO, OGN, RARE, and VRNA
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Scholar Rock (SRRK), Alvotech (ALVO), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.
ARS Pharmaceuticals vs.
Viking Therapeutics (NASDAQ:VKTX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
Viking Therapeutics' return on equity of -12.73% beat ARS Pharmaceuticals' return on equity.
Viking Therapeutics received 600 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 84.00% of users gave ARS Pharmaceuticals an outperform vote while only 79.92% of users gave Viking Therapeutics an outperform vote.
In the previous week, Viking Therapeutics had 3 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 14 mentions for Viking Therapeutics and 11 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.48 beat Viking Therapeutics' score of 0.29 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.
76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ARS Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
Viking Therapeutics presently has a consensus target price of $106.75, suggesting a potential upside of 226.95%. ARS Pharmaceuticals has a consensus target price of $26.00, suggesting a potential upside of 106.84%. Given Viking Therapeutics' higher possible upside, equities analysts plainly believe Viking Therapeutics is more favorable than ARS Pharmaceuticals.
Summary
ARS Pharmaceuticals beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SPRY) was last updated on 1/21/2025 by MarketBeat.com Staff
